Oncolys BioPharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.6%.

Top 18 shareholders own 21.5% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
3.92%	Rakuten Investment Management, Inc.	890,600	JP¥626.1m	0%	0.24%
3.2%	Astellas Pharma Inc.	727,200	JP¥511.2m	0%	no data
3.06%	Central Tanshi Co., Ltd., Asset Management Arm	696,200	JP¥489.4m	0%	1.31%
2.42%	SBI Holdings Inc., Asset Management Arm	551,114	JP¥387.4m	0%	0.12%
2.2%	Yasuo Urata	498,900	JP¥350.7m	0%	no data
1.78%	Evolution Capital Management LLC	405,000	JP¥284.7m	-9.19%	2.39%
0.96%	Hitoshi Nakanishi	219,000	JP¥154.0m	0%	no data
0.9%	Japan Securities Finance Co. Ltd., Asset Management Arm	205,400	JP¥144.4m	0%	0.02%
0.57%	Taizo Kawabata	128,700	JP¥90.5m	0%	no data
0.52%	Asahi Intecc Co., Ltd.	118,600	JP¥83.4m	0%	no data
0.51%	Yasunari Kashihara	115,000	JP¥80.8m	0%	no data
0.48%	Simplex Asset Management Co., Ltd.	109,100	JP¥76.7m	1.39%	0.05%
0.44%	au Kabucom Securities Co., Ltd., Asset Management Arm	100,500	JP¥70.7m	0%	0.32%
0.44%	Matsui Securities Co. Ltd., Asset Management Arm	100,000	JP¥70.3m	0%	0.27%
0.079%	Keiji Yoshimura	18,000	JP¥12.7m	0%	no data
0.0053%	Sumitomo Mitsui Financial Group Inc., Asset Management Arm	1,200	JP¥843.6k	0%	no data
0.0044%	Shiro Ohki	1,000	JP¥703.0k	0%	no data
0.0026%	Katsufusa Tachiya	600	JP¥421.8k	0%	no data